Proof of Concept Study of Gevokizumab in the Treatment of Pyoderma Gangrenosum

An Open-label, Proof of Concept Study of Gevokizumab in the Treatment of the Acute, Inflammatory Phase of Pyoderma Gangrenosum

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01882504

Enrollment

Registered

2013-06-20

Start date

2013-05-31

Completion date

2015-10-31

Last updated

2016-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pyoderma Gangrenosum

Keywords

Pyoderma Gangrenosum, Classic Pyoderma Gangrenosum, Atypical Pyoderma Gangrenosum, Peristomal Pyoderma Gangrenosum

Brief summary

The study will evaluate the safety and biologic activity of gevokizumab in subjects in the acute inflammatory phase of pyoderma gangrenosum.

Interventions

DRUGgevokizumab

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* An established diagnosis of pyoderma gangrenosum * Currently experiencing an inflammatory episode of pyoderma gangrenosum * Contraceptive measures adequate to prevent pregnancy during the study

Exclusion criteria

* Clinical evidence of acutely infected pyoderma gangrenosum * History of allergic or anaphylactic reactions to monoclonal antibodies * History of recurrent or chronic systemic infections * Female subjects who are pregnant, planning to become pregnant, have recently delivered, or are breast-feeding Other protocol-defined inclusion/

Design outcomes

Primary

Measure	Time frame
Improvement in the Investigator's Assessment of the pyoderma gangrenosum target ulcer	Day 1 through Day 84

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026